Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Theralase Technologies Inc
(OP:
TLTFF
)
0.1215
+0.0033 (+2.79%)
Streaming Delayed Price
Updated: 3:11 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Theralase Technologies Inc
< Previous
1
2
3
Next >
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
January 27, 2025
Via
ACCESS Newswire
Theralase(R) Launches Three New Clinical Study Sites in USA
December 09, 2024
Via
ACCESSWIRE
Theralase(R) Launches New Clinical Study Site in Canada
December 05, 2024
Via
ACCESSWIRE
Theralase(R) Release’s 3Q2024 Financial Statements
November 27, 2024
Via
ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement
November 15, 2024
Via
ACCESSWIRE
Theralase(R) Extends Warrants
November 12, 2024
Via
ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
October 07, 2024
Via
ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
September 24, 2024
Via
ACCESSWIRE
Theralase(R) Extends Warrants
September 19, 2024
Via
ACCESSWIRE
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
September 03, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
August 28, 2024
Via
ACCESSWIRE
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
August 21, 2024
Via
ACCESSWIRE
Theralase(R) Release’s 2Q2024 Financial Statements
August 12, 2024
Via
ACCESSWIRE
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
July 08, 2024
Via
ACCESSWIRE
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
June 20, 2024
Via
ACCESSWIRE
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
June 19, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
June 18, 2024
Via
ACCESSWIRE
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
June 14, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy
June 12, 2024
Via
ACCESSWIRE
Ruvidar(TM) Enhances Efficacy of Cancer Drug
June 10, 2024
Via
ACCESSWIRE
Theralase(R) Successfully Destroys Lung Cancer
June 06, 2024
Via
ACCESSWIRE
Theralase(R) Technology Effective in Virus Inactivation
June 04, 2024
Via
ACCESSWIRE
Theralase(R) Release's 1Q2024 Financial Statements
May 30, 2024
Via
ACCESSWIRE
Theralase(R) Expands Clinical Team
May 02, 2024
Via
ACCESSWIRE
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
April 24, 2024
Via
ACCESSWIRE
Theralase(R) Granted Canadian Cancer Vaccine Patent
April 05, 2024
Via
ACCESSWIRE
Theralase(R) Release's 4Q2023 Interim Financial Statements
March 27, 2024
Via
ACCESSWIRE
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
March 26, 2024
Via
ACCESSWIRE
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
February 12, 2024
Via
ACCESSWIRE
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
February 08, 2024
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
